Next Article in Journal
Metal-Based G-Quadruplex Binders for Cancer Theranostics
Next Article in Special Issue
Characterisation of Antiviral Activity of Cathelicidins from Naked Mole Rat and Python bivittatus on Human Herpes Simplex Virus 1
Previous Article in Journal
Photodynamic Therapy Combined with Antibiotics or Antifungals against Microorganisms That Cause Skin and Soft Tissue Infections: A Planktonic and Biofilm Approach to Overcome Resistances
Article

Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library

Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Edmond J. Safra Campus Givat-Ram, Jerusalem 91904, Israel
*
Author to whom correspondence should be addressed.
Academic Editor: Zoidis Grigoris
Pharmaceuticals 2021, 14(7), 604; https://doi.org/10.3390/ph14070604
Received: 25 May 2021 / Revised: 10 June 2021 / Accepted: 11 June 2021 / Published: 23 June 2021
(This article belongs to the Special Issue Antiviral Drugs 2021)
SARS-CoV-2, the etiological agent of the COVID-19 pandemic, is a member of the Coronaviridae family. It is an enveloped virus with ion channels in its membrane, the most characterized of which is the E protein. Therefore, in an attempt to identify blockers of the E channel, we screened a library of 2839 approved-for-human-use drugs. Our approach yielded eight compounds that exhibited appreciable activity in three bacteria-based channel assays. Considering the fact that the E channel is the most conserved of all SARS-CoV-2 proteins, any inhibitor of its activity may provide an option to curb the viral spread. In addition, inhibitors can also enhance our ability to understand the exact role played by the E protein during the infectivity cycle. Finally, detailed electrophysiological analyses, alongside in vitro and in vivo studies will be needed to establish the exact potential of each of the blockers identified in our study. View Full-Text
Keywords: COVID-19; viral channels; bacterial assays; channel blockers; antiviral drugs COVID-19; viral channels; bacterial assays; channel blockers; antiviral drugs
Show Figures

Figure 1

MDPI and ACS Style

Tomar, P.P.S.; Krugliak, M.; Arkin, I.T. Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library. Pharmaceuticals 2021, 14, 604. https://doi.org/10.3390/ph14070604

AMA Style

Tomar PPS, Krugliak M, Arkin IT. Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library. Pharmaceuticals. 2021; 14(7):604. https://doi.org/10.3390/ph14070604

Chicago/Turabian Style

Tomar, Prabhat P.S., Miriam Krugliak, and Isaiah T. Arkin 2021. "Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library" Pharmaceuticals 14, no. 7: 604. https://doi.org/10.3390/ph14070604

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop